ACS and ACS CAN Letter to CMS on Rx Negotiation List
September 14, 2023
ACS and ACS CAN provided comments to the Centers for Medicare and Medicaid Services on the list of Part D drugs selected for the price negotiation program authorized under the Inflation Reduction Act (IRA).
ACS CAN submitted comments to the Consumer Financial Protection Bureau strongly supporting the proposal to prohibit medical debt from appearing on credit reports.
A critical factor for eliminating disparities and ensuring health equity is the guarantee that all people have access to quality, affordable health care.
